[Downloaded free from http://www.ijmr.org.in on Saturday, November 01, 2014, IP: 117.203.194.44] || Click here to download free Android application for this journa
Policy Document
Indian J Med Res 140, September 2014, pp 451-468
Consensus & Evidence-based INOSA Guidelines 2014
(First edition)
Surendra K. Sharma1*, Vishwa Mohan Katoch2*, Alladi Mohan3*, T. Kadhiravan4*, A. Elavarasi1*, R. Ragesh1*,
Neeraj Nischal1*, Prayas Sethi1*, D. Behera5*, Manvir Bhatia6*, A.G. Ghoshal7*, Dipti Gothi8*, Jyotsna Joshi9*,
M.S. Kanwar10*, O.P. Kharbanda1*, Suresh Kumar11*, P.R. Mohapatra12*, B.N. Mallick13*, Ravindra Mehta14*,
Rajendra Prasad15*, S.C. Sharma1*, Kapil Sikka1*, Sandeep Aggarwal1*, Garima Shukla1*, J.C. Suri16*,
B. Vengamma3*, Ashoo Grover2*, V.K. Vijayan17*, N. Ramakrishnan18*, Rasik Gupta2*
for Indian Initiative on Obstructive Sleep Apnoea (INOSA) Guidelines Working Group
Writing Committee of the INOSA guidelines Working Group
All India Institute of Medical Sciences (AIIMS), New Delhi, 2Indian Council of Medical Research (ICMR),
New Delhi, 3Sri Venkateswara Institute of Medical Sciences (SVIMS), Tirupati, 4Jawaharlal Institute of
Postgraduate Medical Education & Research (JIPMER), Puducherry, 5Post Graduate Institute of Medical
Education & Research (PGIMER), Chandigarh, 6Medanta Hospital, Gurgaon, 7National Allergy Asthma
Bronchitis Institute (NAABI), Kolkata, 8Employees’ State Insurance Corporation- Post Graduate Institute of
Medical Sciences & Research (ESI-PGIMSR), New Delhi, 9Topiwala National (TN) Medical College, Mumbai
10
Apollo Hospitals, New Delhi, 11Sree Balaji Medical College & Hospital, Bharath University Chennai, 12AIIMS,
Bhubaneswar, 13School of Life Sciences, Jawaharlal Nehru University (JNU), New Delhi, 14Apollo Hospitals,
Bangalore, 15VP Chest Institute, New Delhi, 16Safdarjung Hospital, New Delhi, 17ICMR, Bhopal & 18Apollo
Hospitals, Chennai, India
*
1
Received September 26, 2014
This statement was prepared by the Writing Group of the INOSA Guidelines based on the Consensus and Evidence-based Guidelines for the
diagnosis and treatment of obstructive sleep apnoea in India framed by the Working Group of INOSA Guidelines.
Other Contributors (names listed alphabetically):
A. Muruganathan, A. Shaheer Ahmed, Abrol Raman, Agarwal A.K., Agarwal Ashish, Ahluwalia Gautam, Athavale Amita U., Bhansali Anil,
Bhasin Dinkar, Bhattacharjee Hemanga K., Chawla Rajesh, Devnani Preeti, Garg Ajay, Gaur S.N., Godbole Gauri, Goyal Vinay, Gupta K.B.,
Jain Sanjay, Jena Ashok, Jha Saket, Jha Sushil D., Joshi Shashank, Kamath Sandhya, Khatiwada Saurav, Kohli Mikashmi, Koul Parvaiz,
Kumar Atin, M. Nandhini, M. Vignesh, Makode Sagar R., Mehndiratta M.M., Mehta Manju, Mishra Narayan, Moses Isaac Christian, Munjal
Y.P., N. Ramakrishnan, Nadkar Milind Y., Naik Ramavath Devendra, Pati A.K., Pawar Satyajit, P.B. Sryma, Preetam C., Raj Swaroop
K., Ranjan Piyush, Rasalkar Pavan, Reddy Harish, Roy D.J., Roy Prasun, Sagar Rajesh, Sahoo R.C., Samaria J.K., Sanas B.B., Sarabhai
Vikram, Shah S.N., Shanmugam Krishnan, Sharma Sanchit, Sinha Sanjeev, Singhal Rajinder, Soneja Manish, Subramanian Krishnnan A,
T. Mohan Kumar, Thakkar Alok, Tiwari Akash, Tripathi Manjari, Tripathi Suryakant, Upadhyay Vishwanath & Varma Subhash
451
[Downloaded free from http://www.ijmr.org.in on Saturday, November 01, 2014, IP: 117.203.194.44] || Click here to download free Android application for this journa
452
INDIAN J MED RES, September 2014
Obstructive sleep apnoea (OSA) and obstructive sleep apnoea syndrome (OSAS) are subsets of sleepdisordered breathing. Awareness about OSA and its consequences amongst the general public as well
as the majority of primary care physcians across India is poor. This necessiated the development of the
INdian initiative on Obstructive sleep apnoea (INOSA) guidelines under the auspices of Department of
Health Research, Ministry of Health & Family Welfare, Government of India. OSA is the occurrence
of an average five or more episodes of obstructive respiratory events per hour of sleep with either sleep
related symptoms or co-morbidities or ≥ 15 such episodes without any sleep related symptoms or comorbidities. OSAS is defined as OSA associated with daytime symptoms, most often excessive sleepiness.
Patients undergoing routine health check-up with snoring, daytime sleepiness, obesity, hypertension,
motor vehicular accidents and high risk cases should undergo a comprehensive sleep evaluation.
Medical examiners evaluating drivers, air pilots, railway drivers and heavy machinery workers should
be educated about OSA and should comprehensively evaluate applicants for OSA. Those suspected to
have OSA on comprehensive sleep evaluation should be referred for a sleep study. Supervised overnight
polysomnography (PSG) is the “gold standard” for evaluation of OSA. Positive airway pressure (PAP)
therapy is the mainstay of treatment of OSA. Oral appliances are indicated for use in patients with mild
to moderate OSA who prefer oral appliances to PAP, or who do not respond to PAP or who fail treatment
attempts with PAP or behavioural measures. Surgical treatment is recommended in patients who have
failed or are intolerant to PAP therapy.
Key words Bariatric surgery - CPAP - Indian guidelines - OSA - OSAS - polysomnography - sleep apnoea - sleep study - Syndrome Z
Introduction
In obstructive sleep apnoea (OSA), repetitive
collapse of the upper airway occurs, that leads to snoring,
frequent episodes of sleep interruption, hypoxemia,
hypercapnia, swings in intrathoracic pressure and
increased sympathetic activity. Management of OSA
needs a long-term multi-disciplinary approach. Once
diagnosed, patients should be properly counselled to
manage their illness including co-morbidities through
their active participation.
OSA is being increasingly recognized as an
emerging important public health problem worldwide,
including India. Awareness among lay public and
even among primary care physicians is dismally
low in India. This disorder is common among obese
individuals, children and post-menopausal women.
It is usually associated with several co-morbidities
such as insulin resistance, metabolic syndrome,
diabetes mellitus, hypertension, stroke, coronary
artery disease, increased risk of vehicular accidents
and various psychiatric disorders. Though there are
guidelines regarding the diagnosis and management of
this condition by various bodies in the western world,
these recommendations may not be entirely applicable
to the developing countries like India. There was a
need to develop comprehensive guidelines on OSA in
the Indian context. Thus, the consensus and evidencebased INdian initiative on Obstructive Sleep Apnoea
Guidelines (INOSA Guidelines) were developed
under the auspices of Department of Health Research,
Ministry of Health & Family Welfare, Government of
India following a series of meetings and discussions
under the convenership of the Department of Medicine,
All India Institute of Medical Sciences (AIIMS), New
Delhi, with the support of Indian Council of Medical
Resaerch (ICMR). During this first Indian initiative, in
light of the available evidence, consensus statements
were developed and finalized by the various national
experts in the field of sleep medicine including internists,
pulmonologists, neurologists, otorhinolaryngologists,
endocrinologists, bariatric surgeons and dental
surgeons.
In order to make the guidelines evidence based,
the expert group reviewed the available evidence and
graded the recommendations according to the quality
of evidence as mentioned in Fig. 11.
1 Epidemiology and risk factors of OSA
1.1 Epidemiology
Obstructive sleep apnoea is a major public health
problem. The International Classification of Sleep
Disorders, Third Edition classifies sleep-disordered
breathing into three basic categories: central sleep
apnoea syndrome, obstructive sleep apnoea syndrome,
and sleep-related hypoventilation/hypoxia syndrome2,3.
Community-based epidemiological studies from several
parts of India have estimated that the prevalence of
OSAS is 2.4 to 4.96 per cent in men and 1 to 2 per cent
[Downloaded free from http://www.ijmr.org.in on Saturday, November 01, 2014, IP: 117.203.194.44] || Click here to download free Android application for this journa
sharma et al: INOSA Guidelines 2014
Preponderance
of Benefit or
Harm
Evidence Quality
A. Well designed RCTs or diagnostic studies
on relevant population
B. RCTs or diagnostic studies with minor
limitations; overwhelmingly consistent
evidence from observational studies
Strong
Recommendation
C. Observational studies (case-control and
cohort design)
Recommendation
D. Expert opinion, case reports, reasoning
from first principles
X. Exceptional situations where validating
studies cannot be performed and there is a
clear preponderance of benefit or harm
Option
453
Balance of
Benefit and
Harm
Option
No Rec
Strong
Recommendation
Recommendation
Fig. 1. Evidence quality. Reproduced with permission from: American Academy of Pediatrics Steering Committee on Quality Improvement
and Management. Classifying recommendations for clinical practice guidelines.Pediatrics 2004; 114 : 874-71.
in women4. Table I summarizes some of the important
definitions5.
1.2 Pathogenesis
Multiple factors (Table II)6,7 are responsible for
pathogenesis of OSA with inter-individual variation.
OSA patients have repeated narrowing or obstruction of
pharyngeal airway during sleep. It has been suggested
that pathophysiological mechanisms, such as anatomic
compromise, pharyngeal dilator muscle dysfunction,
lowered arousal threshold, ventilatory control
instability, and/or reduced lung volume tethering are
the pathophysiological mechanisms leading to OSA8.
2 Consequences of OSA
2.1 OSA and Mortality
It has been demonstrated that OSA is associated
with increased mortality. Severe sleep disordered
breathing (SDB) has a 3.8 fold greater risk for all-cause
mortality and 5.2-fold greater risk for cardiovascular
mortality than those without SDB (Evidence Quality
B)9. The consequences of OSA are described in Table
III4,10-26.
3 Diagnosis of OSA
3.1 History and Physical Examination
The diagnosis of OSA requires a high index of
suspicion. OSA may be suspected during routine health
check-up or while evaluating high-risk patients27. The
chances of underdiagnosis are minimized if individuals
with risk factors are subjected to a comprehensive sleep
evaluation during routine health check-up. Similarly,
high-risk patients like those with congestive heart
failure, extreme obesity, diabetes mellitus, coronary
artery disease, stroke, nocturnal dysrhythmias including
atrial fibrillation, pulmonary hypertension, preoperative
patients should have comprehensive sleep evaluation
(Boxes 1 and 2)27. Additionally, medical examiners
evaluating drivers, pilots, railway drivers and heavy
machinery workers should be educated about OSA and
should refer them for evaluation if snoring, daytime
sleepiness or obesity is noted (Evidence Quality B,
Strong Recommendation).
In a patient suspected to have OSA, secondary
causes such as hypothyroidism, facial abnormality,
tonsil/adenoid hypertrophy and musculoskeletal
abnormalities should be ruled out and the patient
should be evaluated for consequences of OSA like
metabolic syndrome, diabetes mellitus, hypertension,
CAD, stroke and gastroesophageal reflux27,28. Patient
should also be investigated for associated co-morbid
illnesses like allergic rhinosinusitis, nasal polyps,
asthma, chronic obstructive pulmonary disease
(COPD), obesity hypoventilation syndrome and
kyphoscoliosis27,28. The clinical examination should
include detailed anthropometry including measurement
of neck circumference, BMI, modified Mallampati
score and a comprehensive upper airway assessment27.
[Downloaded free from http://www.ijmr.org.in on Saturday, November 01, 2014, IP: 117.203.194.44] || Click here to download free Android application for this journa
454
INDIAN J MED RES, September 2014
Table I. Definitions5
Apnoea
Apnoea is defined as cessation of breathing or airflow for 10 seconds or longer in a
polysomnography5.
•
Obstructive apnoea
There is no airflow at nose or mouth but there are persistent respiratory efforts.
•
Central apnoea
There is no airflow at nose or mouth as well as no respiratory effort.
•
Mixed apnoea
It is a mixture of central and obstructive apnoea features.
Apnoea-hypopnoea index (AHI)
AHI is calculated as number of apnoeas and hypopnoeas per hour of sleep.
Respiratory disturbance index (RDI)
RDI is the number of apnoeas, hypopneas and respiratory effort related arousals
(RERAs) per hour of sleep, confirmed by EEG.
Hypopnoea
A hypopnoea5 is defined by the presence of a clear decrease in the amplitude of
airflow (quantitative or semi-quantitative) of >30% from baseline during sleep
•
Or
A clear amplitude reduction of a valid measure of breathing during sleep that does
not reach the above criterion, but is associated with either an oxygen desaturation of
>3 per cent or an arousal
•
And
The event lasts 10 seconds or longer.
Overlap syndrome
The co-occurrence of both chronic obstructive pulmonary disease and OSA in the
same individual is termed as overlap syndrome. Both are common diseases affecting
adult population over 40 years of age.
Polysomnography (Psg)
PSG is a comprehensive in-laboratory overnight recording of different biophysiological changes that occur during sleep.
Respiratory effort related arousal (RERA)
A RERA is defined as an arousal from sleep that follows a 10 second or longer
sequence of breaths that are characterized by increasing respiratory effort, but which
does not meet criteria for an apnoea or hypopnoea5. Snoring is usually but not always
associated with this condition. Oesophageal pressure monitoring is used to measure
respiratory effort; the pattern is of increasing negative pressure, terminated by a
sudden change to a less negative pressure and a cortical arousal. Nasal pressure
signal is a useful alternative to oesophageal pressure monitoring which allows
RERAs to be detected non-invasively.
Upper airway resistance syndrome (UARS)
UARS is a condition in which patients have symptoms suggestive of OSA and
frequent RERAs but AHI <5 events/h.
3.2 Other Diagnostic Investigations
Anthropometric measurements, nasal and upper
airway examination, orthodontic assessments and
radiological measurements have low sensitivity and
specificity when used alone for diagnosis of OSA28.
Patients suspected to have OSA should be referred
for an appropriate type of sleep study after detailed
history, examination and basic investigations. Various
questionnaires for the prediction of OSA are available
and can be used prior to sleep study, but the same is not
mandatory.
3.3 Epworth Sleepiness Scale (ESS)
Epworth Sleepiness Scale is a simple, selfadministered measurement of sleep propensity during
daytime in adults that requires the subject to rate the
probability of dozing off in eight different situations
that are met in day-to-day life on a scale of 0-3. Thus,
the sum of the score can vary from 0 to 24. ESS score
>10 is defined as excessive daytime sleepiness and
has a sensitivity of 49 per cent and specificity of 80
per cent for predicting OSA29. (Evidence Quality C,
Recommended).
3.4 Clinical prediction rules for OSA
Various algorithms have been devised for
screening and risk stratification of patients suspected
to have OSA. The utility of these tools to estimate the
clinical severity of OSA and to suggest the likelihood
of OSA related consequences have not been studied
systematically30.
[Downloaded free from http://www.ijmr.org.in on Saturday, November 01, 2014, IP: 117.203.194.44] || Click here to download free Android application for this journa
sharma et al: INOSA Guidelines 2014
Table II. Risk factors for obstructive sleep apnoea6,7
Demographic characteristics
Older age
Male gender
Pregnancy
Risk factors linked to OSA by strong published evidence
Obesity
Central body fat distribution
Neck circumference
Anatomical abnormalities of the craniofacial region and
upper airway specific syndromes (e.g.,Treacher-Collins
syndrome, Pierre Robbins syndrome)
Retroposed mandible/maxillae, hypertrophied tonsils,
tongue
Other suspected (potential) risk factors
Genetic predisposition
Familial aggregation
Tobacco smoking
Menopause
Alcohol use
Night time nasal congestion
Endocrine abnormalities: hypothyroidism/acromegaly
Polycystic ovarian syndrome
Down’s syndrome
Drugs e.g., benzodiazepines, muscle relaxants,
testosterone therapy
Berlin questionnaire has three categories of
questions. Category 1 questions are about snoring
with five questions and 2 to 5 multiple choice answers.
Category 2 includes excessive daytime sleepiness with
four or more multiple choice answers. Category 3 has
body mass index (BMI) and blood pressure. With Berlin
questionnaire, OSA was considered probable if two of
the categories are positive. The Berlin questionnaire
was modified at AIIMS, New Delhi, in 2006 for
application in the setting of developing countries31.
Both Berlin questionnaire and modified Berlin
questionnaire are moderately accurate (sensitivity and
specificity generally <90%) in screening for OSA30,31
(Evidence Quality C; Recommended). Although, these
questionnaires have not been adequately studied, these
can be used to screen the patients for OSA. The snoring,
daytime tiredness, observed apnoea, high blood
pressure, body mass index, age, neck circumference,
and gender (STOP-BANG) questionnaire (Evidence
455
Quality C, Recommended) is the most appropriate
questionnaire for the screening in preoperative cases.
Patients who have both symptoms and physical
findings suggestive of OSA on comprehensive sleep
evaluation along with Epworth’s sleepiness score
greater than or equal to 10 have a high risk of OSA
and the diagnosis is confirmed and severity determined
with objective testing in an expedited manner in order
to initiate treatment. Patients who have neither are at
low probability and the rest have moderate probability
for OSA. Fig. 2 shows the algorithm for the diagnosis
of OSA.
3.5 Types of Sleep Study
The diagnosis and severity of OSA must be
ascertained before initiating the treatment of OSA.
The standard diagnostic test for OSA is an attended
in-laboratory polysomnography (PSG) or portable
monitoring (PM)27. PSG is supervised by a trained
technician with at least seven channels whereas PM is
performed without a technician and has fewer channels.
Various types of sleep studies are described in Fig. 3.
In laboratory PSG with electroencephalography (EEG)
based sleep staging, the “gold standard” for the diagnosis
of OSA is not necessary in all patients suspected to
have OSA28. Portable monitoring with type 3 and
4 devices in conjunction with comprehensive sleep
evaluation is adequate for diagnosis of OSA in patients
with high pre-test probability of moderate to severe
OSA without co-morbid sleep or medical disorders
such as neuromuscular disease, pulmonary disease, or
congestive heart failure (Evidence Quality A, Strong
Recommendation)32. PSG is mainly useful for patients
with symptoms of excessive daytime sleepiness but no
objective evidence of obstructive sleep apnoea on PM
(Box 3).
3.5.1 Attended in-laboratory polysomnography Type 1 Sleep Study: Type 1 study or in-laboratory,
technician-attended, overnight PSG is the present
reference or “gold” standard for evaluation of sleep
and sleep-disordered breathing (Evidence Quality
A, Strong Recommendation)33. The recommended
parameters to be evaluated in PSG include sleep state
and stages, ventilatory parameters, cardiac function
and limb movements34 by recording EEG, electrooculography (EOG), electrocardiography (ECG),
chin and leg electromyography (EMG), nasal and
oral airflow, chest and abdominal efforts and pulse
oximetry33. The study requires the constant presence
of a trained individual with appropriate sleep-related
[Downloaded free from http://www.ijmr.org.in on Saturday, November 01, 2014, IP: 117.203.194.44] || Click here to download free Android application for this journa
456
INDIAN J MED RES, September 2014
Table III. Consequences of OSA4,10-26
Hypertension
OSA is an independent risk factor for systemic hypertension (Evidence Quality A)10. Several
studies have shown an increased prevalence of hypertension in patients with OSA (Evidence
Quality A)11. Increase in one additional apnoeic event per hour of sleep enhances the odds of
developing hypertension by about 1 .The odds of developing hypertension increases by 13
per cent with 10 per cent decline in nocturnal oxygen saturation.
Resistant hypertension
OSA is a very important but often missed diagnosis in patients with resistant hypertension.
All patients with resistant hypertension should be evaluated for OSA (Evidence Quality A,
Recommended)12.
Coronary artery disease
There is an increased prevalence of coronary artery disease in OSA patients (Evidence
Quality B). Studies have shown a graded increase in the risk of acute myocardial infarction
with increasing AHI13.
Congestive heart failure
There is a high prevalence of OSA among patients with symptomatic heart failure with
reduced ejection fraction (HFrEF) (Evidence Quality B)14.
Arrhythmias
OSA is independently associated with a high frequency of nocturnal arrhythmias such as
atrial fibrillation, complex ventricular ectopy, and non-sustained ventricular tachycardia.
(Evidence Quality B)15.
Cerebrovascular disease
OSA is associated with increased risk of stroke. Patients with recurrent strokes had a higher
percentage of OSA (AHI > 10) than initial strokes (74% compared to 57%) (Evidence Quality
B)16.
Diabetes mellitus (DM)
The prevalence of OSA in diabetic and pre-diabetic obese patients is higher than those with
normal glucose tolerance. Moreover, the risk of developing type 2 DM increases with the
severity of OSA (Evidence Quality B)17.
Dyslipidaemia
OSA is independently associated with increased total cholesterol and LDL cholesterol levels,
and carotid intima-media thickness irrespective of the cardiovascular co-morbidity. RCTs
have shown that PAP therapy may produce a clinically relevant fall in total cholesterol level,
potentially reducing cardiovascular risk (Evidence Quality A)18.
Metabolic syndrome
OSAS has been shown to be strongly and independently associated with metabolic syndrome19.
The combination of OSA and metabolic syndrome is called Syndrome Z. The prevalence of
metabolic syndrome varies from 74 to 85 per cent among patients with OSA as compared to
37 to 41 per cent among patients with no OSA. (Evidence Quality C)4.
OSA and neurocognitive function
Slow thought process, early forgetfulness, impaired concentration and decreased work related
performance have been observed in OSA (Evidence Quality C)20. Impairment in verbal
episodic memory, visuo-spatial episodic memory, attention span, driving ability, vigilance,
executive function, have been associated with OSA (Evidence Quality B)21.
OSA and excessive daytime sleepiness
Excessive daytime sleepiness in OSA has been associated with increased risk of motor
vehicle accidents22 (Evidence Quality B).
OSA & Psychiatric disorders
There is high prevalence of depression in patients with OSA, especially in females (Evidence
Quality C)23. All patients with erectile dysfunction24 (Evidence Quality B: Recommendation)
should be screened for OSA.
OSA and quality of life
Studies have shown impaired quality of life in OSA with correlation of arousal index with
physical function, general health and physical roles which improves with PAP therapy
(Evidence Quality B)25.
OSA and economic impact
Potential costs attributable to OSA include the costs of diagnosis and treatment, the decrement
in quality of life, the medical consequences, motor vehicle accidents, and occupational losses
(Evidence Quality B)26.
[Downloaded free from http://www.ijmr.org.in on Saturday, November 01, 2014, IP: 117.203.194.44] || Click here to download free Android application for this journa
sharma et al: INOSA Guidelines 2014
457
Box 1. Symptoms of OSAS
Nocturnal
•
•
•
•
•
Snoring: Is it loud? Is it audible in the other room? Is it crescendo-decrescendo in nature? Does he/she wake up with one’s own
snoring?
Witnessed apnoea: Has the partner witnessed apnoeas or sudden interruption in the loud snoring sound?
Nocturnal choking: Does he/she wake up with a gasping or choking sensation?
Nocturia: How many times does he/she wake up due to nocturia?
Sleep quality: Is the sleep disturbed with tossing and turning? Is there frequent sleep fragmentation and difficulty in maintaining
sleep leading to insomnia? What is the total amount of sleep? Is there a feeling of un-refreshing sleep or early morning headache
or dryness of throat?
Daytime
•
•
•
•
•
Excessive daytime sleepiness: Does the patient feel sleepy during quiet activities like reading, watching television or during
activities that generally require alertness like school, work, driving.
Lethargy: Does he/she have daytime fatigue/tiredness, decreased alertness?
Cognitive deficits: History of memory loss, poor concentration and intellectual impairment.
Psychiatric symptoms: Personality and mood changes, depression, anxiety, sexual dysfunction like impotence and decreased
libido.
Systemic complaints: Gastroesophageal reflux, hypertension, diabetes.
In patients with nocturia, UTI and BPH (in males) should be ruled out
*
Box 2. Clinical examination finding suggestive of OSAS
•
•
•
•
Neck circumference >16 inches (40.6 cm) in women and > 17 inches (43.2 cm) in men
Body mass index ≥ 30 kg/m2
Modified Mallampati score 3 or 4
Upper airway evaluation showing retrognathia, high arched palate, macroglossia, tonsillar hypertrophy, enlarged uvula, nasal
abnormality
training who can monitor patient compliance, technical
adequacy and relevant patient behaviour (Evidence
Quality B, Recommended)27. It is advisable to take
prior informed consent for PSG. Social acceptability
of full-night PSG for women is an issue in the
Indian context. Full-night PSG is recommended for
the diagnosis of OSA (Evidence Quality A, Strong
Recommendation).
3.5.2 Unattended polysomnography-Type 2 Sleep
Study: Type 2 devices can record the same variables
as type 1 study in absence of a technician. Thus, type
2 sleep monitoring can be practically used as portable
monitors, but is not used frequently in the outpatient
setting. Type 2 study may identify apnoea hypopnoea
index (AHI) suggestive of OSA with high positive
likelihood ratio and low negative likelihood ratio,
though differences in AHI have been encountered
between type 2 study and PSG30,35 (Evidence Quality
B, Recommended).
3.5.3 Portable monitoring/Out-of-centre sleep testing
(OCST)/Home Sleep Testing (HST)/Unattended Limited
Channel Testing (ULCT) (Type 3 & 4 Sleep Study):
Portable monitoring or OCST as a diagnostic test for
OSA has evolved as an alternative to PSG27 due to
convenience and lower cost. The disadvantage of PM
or OCST, however, is that AHI may be falsely low30,36.
This is because in the absence of EEG recording in
these tests, actual sleep time cannot be determined and
the the denominator is the total recording time instead
of the total sleep time. Comprehensive sleep evaluation
should always be done prior to PM studies27.
The diagnosis and severity assessment should be
performed using the same definitions as used for PSG.
PM should be performed only in conjunction with
comprehensive sleep evaluation and in the presence
of a practitioner eligible for conducting sleep studies
(Evidence Quality B, Recommended)32. Overall,
PM (type 3 and 4) may be useful, cost-effective,
convenient and speedy method of diagnosis if the
patient is selected carefully. Hospital-based PSG is
the investigation of choice for patients who cannot be
investigated adequately at home or whose home study
result does not match with the clinical suspicion of the
investigating physician28.
[Downloaded free from http://www.ijmr.org.in on Saturday, November 01, 2014, IP: 117.203.194.44] || Click here to download free Android application for this journa
458
INDIAN J MED RES, September 2014
Fig. 2. Algorithm for diagnosis of OSA. *Boxes 1 and 2 †Pulmonary disease, neuromuscular disease, or congestive heart failure. PM, portable
monitoring; PSG, polysomnography.
3.6 Preoperative Evaluation of OSA
The incidence of post-operative desaturation,
respiratory failure, post-operative cardiac events and
intensive care unit transfers is higher in patients with
OSA (Evidence Quality A, Strong Recommendation)37.
Both PSG and portable monitoring are helpful in
diagnosing and categorizing the severity of OSA, but
portable monitoring reduces the likelihood of delay in
the surgery, inconvenience and high cost of laboratory
study. Alternatively, in a case at high risk of OSA, sleep
study may be deferred if it is not feasible or causes delay
in surgery. Instead, a standby positive airway pressure
device with a close monitoring may be advised38.
Patients who have previously been diagnosed to have
OSA must be asked to use positive airway pressure
(PAP) preoperatively and postoperatively.
3.7 Diagnostic criteria for OSA
The diagnostic crieteria for OSA are summarized
in Box 4.
[Downloaded free from http://www.ijmr.org.in on Saturday, November 01, 2014, IP: 117.203.194.44] || Click here to download free Android application for this journa
sharma et al: INOSA Guidelines 2014
459
Fig. 3. Types of sleep studies. Type 1: Fully attended polysomnography (≥ 7 channels) in a laboratory setting, Type 2: Fully unattended
polysomnography (≥ 7 channels), Type 3: Limited channel study (usually using 4-7 channels), Type 4: 1 or 2 channels usually using oximetry
as one of the parameters, EEG, electroencephalography; EOG, electro-oculography; EMG, electromyography; ECG, electrocardiography.
3.8 Optimal continuous positive airway pressure
(CPAP) titration
Optimal PAP to treat OSA is the effective pressure
that eliminates sleep-disordered breathing events in
all sleep positions and stages, particularly REM (rapid
eye movement) sleep, improving sleep quality without
creating any untoward pressure-related side effects for
the patient.
Titration effectiveness has been described by a
grading system, detailed below39.
A. Optimal titration: AHI < 5 per hour and includes
supine REM sleep.
B. Good titration: AHI < 10 per hour or reduced
by 50 per cent if the baseline less than 15 per hour and
includes supine REM.
C. Adequate titration: AHI cannot be reduced to
less than 10 per hour, but is reduced by 75 per cent
from baseline or criterion for optimal or good titration
is attained, but without supine REM sleep.
D. Unacceptable titration: Any one of the above
grades is not met, which requires a repeat titration.
3.9 Process of PAP Titration
CPAP titration is done by starting at a minimum
pressure of 4 cm water (H2O) which is then increased
by 1 cm H2O to a maximum of 20 cm H2O every five
minutes or more, with the target of eliminating all the
events (Evidence QualityA, Strong Recommendation)40.
If this pressure does not allow adequate titration,
bilevel positive airway pressure (BPAP) titration is
recommended (Evidence Quality C, Recommended)41.
Box 3. Indications of portable monitoring (PM) and polysomnography (PSG)
Portable monitoring
•
•
•
Patients with high pre-test probability of moderate to severe OSA.
Patients for whom in-laboratory PSG is not possible by virtue of immobility, safety, or critical illness.
To monitor response to non-PAP treatments for OSA including oral appliances, upper airway surgery, and weight loss.
Polysomnography
•
•
•
•
Patients with significant co-morbid medical conditions (moderate to severe pulmonary disease, neuromuscular disease, congestive
heart failure).
Patients with EDS where PM is negative.
Patients suspected to have other sleep disorders.
Screening of asymptomatic high risk populations with heart failure, morbid obesity, diabetes, coronary artery disease, stroke,
refractory hypertension, nocturnal dysrhythmias and atrial fibrillation.
OSA, Obstructive sleep apnoea; PAP, positive airway pressure; EDS, Excessive daytime sleepiness
[Downloaded free from http://www.ijmr.org.in on Saturday, November 01, 2014, IP: 117.203.194.44] || Click here to download free Android application for this journa
460
INDIAN J MED RES, September 2014
Box 4. Criteria for diagnosis of OSA2
The diagnostic criteria for OSA as recommended in International Classification of Sleep Disorders, 3rd Edition, 2014 are the presence
of (A and B) or C
A.
Presence of one or more of the following:
(a) Complains of sleepiness, nonrestorative sleep, fatigue, or symptoms of insomnia.
(b) Waking up with breath holding, gasping, or choking.
(c) Habitual snoring, interruptions in breathing, or both during sleep as reported by patient’s bed partner or other observer.
(d) Co-existing morbidities such as hypertension, type 2 diabetes mellitus, coronary artery disease, congestive heart failure,atrial
fibrillation, stroke,mood disorder, or cognitive dysfunction.
B.
PSG or OCST demonstrates
(a) Five or more obstructive respiratory events (apnoeas, hypopnoeas, or RERAs) per hour of sleep during a PSG or per hour of
monitoring with OCST.
OR
C.
PSG or OCST demonstrates
(a) Fifteen or more obstructive respiratory events (apnoeas, hypopnoeas, or RERAs) per hour of sleep during a PSG or per hour
of monitoring with OSCT, even in the absence of symptoms.
PSG, polysomnography; OCST, out-of-centre sleep testing; RERA, respiratory effort related arousal
Ideally, 15 min of supine REM sleep must be a part of
the titration.
3.10 Split Night vs. Single Night Titration
Full-night PSG with attended manual PAP titration
is regarded as the gold standard for prescription of PAP
therapy (Evidence Quality A, Strong Recommendation).
However, split-night study, i.e., initial PSG followed
by 3 h of PAP titration may be performed if AHI is
>40 events/hour during the first two hours or between
20-40 events/hour with clinical judgment regarding
definitiveness of prescribing PAP therapy (Evidence
Quality A, Strong Recommendation). It is recommended
that the arousals should be abolished with PAP;
otherwise, a repeat study with PSG is indicated for PAP
titration42. AutoPAP titration using autoPAP devices
that monitor snoring, apnoea or hypopnoea by airflow,
flow contour, and/or impedance by forced oscillation
technique can be tried during attended titration
with PSG (Evidence Quality B, Recommended) to
determine a fixed PAP level in patients with moderate
to severe OSA without significant co-morbid illness
such as congestive heart failure (CHF), COPD, central
sleep apnoea or hypoventilation syndromes (Evidence
Quality B, Recommended).
4 Medical management of OSA
4.1 General measures, including pharmacotherapy43-47
The general measures in the management of OSA
are summarized in Box 5.
4.2 Pharmacotherapy in OSA
Several drugs have been tried in OSA in small trials
and the data at present are insufficient to recommend
primary drug treatment in OSA. Wake promoting
agents - modafinil and armodafinil are the only agents
approved for excessive daytime sleepiness (EDS)
despite adequate PAP therapy in OSA patients48,49.
(Evidence Quality A, Strong Recommendation).
4.3 Positive airway pressure therapy
4.3.1 Introduction - The principle of positive
airway pressure in OSA is based on providing air under
positive pressure through an interface (nasal or face
mask), thus creating a pneumatic splint in the upper
airway which prevents collapse of the pharyngeal
airway, acting at all potential levels of obstruction50.
PAP is the most effective and widely used treatment for
OSA and is the first-line therapy for moderate to severe
OSA. PAP improves quality of life, in terms of clearcut reductions in daytime sleepiness and quality of
life measures. Effective PAP therapy reduces snoring
and nocturnal respiratory disturbances and improves
nocturnal oxygenation and sleep architecture. Benefits
of PAP therapy include reduced daytime sleepiness,
improved driving performance, health status and
improvement in neuro-cognitive performance.
Positive effects on cardiovascular outcomes, such
as hypertension, cardiac arrhythmias, nocturnal
ischaemia, left ventricular function, and even overall
mortality have been reported51-53.
[Downloaded free from http://www.ijmr.org.in on Saturday, November 01, 2014, IP: 117.203.194.44] || Click here to download free Android application for this journa
sharma et al: INOSA Guidelines 2014
Box 5. General measures for treating OSA43-47
•
Counselling regarding smoking cessation (Evidence
Quality B, Strong Recommendation).
•
Avoidance of alcohol, sedatives and nicotine (Evidence
Quality D, Optional Recommendation).
•
Treatment of nasal obstruction in consultation with
otonasolaryngologist (Evidence Quality C, Optional
Recommendation).
•
Weight loss (Evidence
Recommendation).
•
Positional therapy (Evidence Quality C, Optional
Recommendation).
•
Counselling about sleep hygiene and avoidance of sleep
deprivation.
Quality
B,
Strong
4.3.2 Indications for CPAP and BPAP - CPAP is
currently the ‘gold standard’ for treatment of moderate
to severe OSA (AHI >15 h), and an option for less
severe OSA. Treatment of OSA is indicated with the
following criteria on PSG: (Evidence Quality A, Strong
Recommendation)10,54-56.
1. AHI or (RDI) ≥ 15 events/h
2. AHI (or RDI) ≥5 but <15 events/h with any of
the following symptoms:
(i) Excessive daytime sleepiness (confirmed by
either a score of greater than 10 on ESS or inappropriate
daytime napping (e.g. during driving, conversation, or
eating) or sleepiness that interferes with daily activities
on a regular basis.
(ii) Impaired cognition or mood disorders.
(iii) Hypertension.
(iv) Ischaemic heart disease.
(v) History of stroke.
(vi) Cardiac arrhythmias.
(vii) Pulmonary hypertension.
All these factors have to be taken into account
while planning treatment of OSA.
Currently, three types of PAP devices are available
for treatment of OSA: continuous PAP (CPAP), bilevel PAP (BPAP), and automatic self-adjusting PAP
(APAP). CPAP devices generate a fixed continuous
pressure during inspiration and expiration. In BPAP,
the pressure alternates between a fixed inspiratory and
lower expiratory level during the respiratory cycle,
which allows differential titration of the inspiratory
(IPAP) and expiratory positive airway pressures
461
(EPAP). In APAP, the pressure changes throughout
the night in response to changes in airflow, respiratory
events, and snoring. There is no evidence base to
choose the modality of PAP.
4.3.3 Role of supplemental oxygen - Supplemental
oxygen (O2) is used after adequate CPAP/BPAP titration,
for residual sleep-related hypoxemia. Specifically, O2
supplementation is done during the PAP titration study,
if the SpO2 is less than 88 per cent for five or more
minutes in the absence of sleep-disordered breathing
events, and oxygen flow rate is increased at a rate of 1
l/min every 15 min to target SpO2 ≥88 per cent. Patients
on O2 prior to PAP titration usually need a higher
amount of O2 with the PAP device due to flow related
dilution of the supplied O2. Supplemental O2 is to be
connected to the PAP device outlet and not to the mask.
The possibility of a rise in CO2 due to the supplemental
O2 is to be kept in mind, and should be monitored with
an arterial blood gas next day after disconnecting the
PAP device.
4.3.4 Recommendations for APAP57-58 - APAP is
a concept based on continuously adjusting positive
airway pressure to meet the patient’s variable needs
to maintain a patent airway, thereby reducing the
overall mean airway pressure. This could be done
in an unattended setting such as the patient’s home,
and potentially enhances tolerability and compliance.
Figure 4 summarises PAP prescription.
1. Certain APAP devices may be useful for attended
titration with PSG to identify a single pressure for use
with standard CPAP [also called fixed CPAP (f-CPAP)]
for management of moderate to severe OSA. (Evidence
Quality B, Optional Recommendation)
2. Patients who are being treated with APAP
itself, or f-CPAP calculated on the basis of APAP
titration must have close clinical follow up to monitor
treatment effectiveness. In the event of an inadequate
symptomatic or objective response with APAP therapy,
a standard attended CPAP titration should be done.
3. APAP devices are not recommended for
split-night titration. (Evidence Quality A, Strong
Recommendation)
4. Patients with CHF, COPD, CSA are not currently
considered candidates for APAP titration or treatment.
(Evidence Quality A, Not Recommended).
4.3.5 PAP compliance59 - The treatment of sleep
apnoea with PAP has inherent problems with initial
acceptance and long-term adherence, together called
[Downloaded free from http://www.ijmr.org.in on Saturday, November 01, 2014, IP: 117.203.194.44] || Click here to download free Android application for this journa
462
INDIAN J MED RES, September 2014
compliance due to discomfort from the mask interface,
positive pressure itself, need for daily night use and
long-term therapy. Compliance with PAP is a significant
problem, and nasal congestion and mask intolerance
are the most common complaints that reduce PAP
compliance.
Some patients cannot tolerate PAP because of
initial discomfort of sudden application of pressure,
or discomfort perceived in exhaling against high
pressure. Most PAP devices have a pressure “ramp”,
where the pressure rise can be slow till it attains the
target pressure, over as much as 45 min. An option for
reducing expiratory pressure is BPAP, which allows
independent adjustment of inspiratory and expiratory
pressures, though the comfort benefits of BPAP have
not been categorically demonstrated. Pressure-relief
CPAP reduces the discomfort of breathing against high
pressure during expiration by lowering the pressure
at the onset of expiration. Recent Cochrane database
review has concluded that pressure-relief CPAP did not
improve compliance60. Similarly, APAP, with a lower
mean pressure through the night has a minimal impact
on improving compliance.
4.3.6 Adverse effects of PAP therapy - Adverse
effects of PAP therapy are summarized in Table IV.
4.4 Oral Appliances
4.4.1 Background and rationale - Oral appliances
(OA) are an established treatment option for snoring
and mild to moderate OSA in selected cases and not
in severe OSA. OAs are less cumbersome than PAP
therapy and should be considered for patients who have
failed or refused PAP treatment, for those with snoring
or mild to moderate OSA61,62. Dental professionals
trained in sleep medicine should prescribe and prepare
appropriately fitting OA for the treatment of OSA.
4.4.2 Types of oral appliances
4.4.2.1 Mandibular repositioning appliance:
Mandibular repositioning appliance (MRA) works by
bringing the mandible forward, thereby increasing the
airway volume. It can be either fixed (pre-determined
advancement), titratable (adjustable) or either a onepiece or a two-piece appliance. The titratable MRA
has an adjustable mechanism that allows progressive
advancement of the mandible after initial construction
until the optimal mandibular position is achieved.
Single-piece or non-adjustable appliances often have
to be made again if the initial jaw advancement is
insufficient62,63.
4.4.2.2 Tongue retaining appliances: Tongue
retaining appliances (TRA) are indicated for patients
with large tongue and when use of MRA is limited
due to edentulous ridges. Once the patient is using
the appliance routinely, overnight PSG is required to
assess the clinical response objectively62,63.
4.4.3 Effects of OA therapy - Effects of OA therapy
are summarized in Table V61,63-70.
4.4.4 Contraindications to OA therapy62,71,72 Contraindications to OA therapy are summarized in
Box 6.
4.4.5 Predictors of response to oral appliances73,74
- Predictors of response to oral appliances are
summarized in Box 7.
4.4.6 Adverse effects of OAs75-77 - Adverse effects
of OAs are summarised in Box 8.
4.4.7 Compliance with OAs - The compliance
depends on benefits and discomfort. Various studies
reported different level of compliance for different
types of OAs in OSA; it ranges from 51 to 88 per cent.
Among the various types of oral appliances, compliance
Table IV. Adverse effects of PAP therapy
Problem
Solution
Nasal congestion, rhinorrhoea, nasal dryness, sinus pain
Nasal steroids, heated humidification
Mask discomfort, leakage
Using suitable mask interface, good mask fitting
Skin breakdown, abrasions
Gel and air-cushion interface masks
Mask claustrophobia
Other types of masks, nasal pillows
Pressure intolerance, difficulty in exhalation
Use “ramp”, pressure-relief, BPAP, auto-PAP
Mouth breathing
Chin strap, full face or oro-nasal mask
Bed partner intolerance
Teaching adaptation skills to the patient and bed partner
[Downloaded free from http://www.ijmr.org.in on Saturday, November 01, 2014, IP: 117.203.194.44] || Click here to download free Android application for this journa
sharma et al: INOSA Guidelines 2014
463
Table V. Effects of oral appliances (OAs)
Effects on snoring
OAs are beneficial in decreasing snoring in the majority of OSA patients on both subjective and
objective assessment63,64. (Evidence Quality A)
Effects on OSA
OAs are effective in the treatment of mild to moderate OSA61 with improvement in the AHI and
oxygen saturation following OA therapy61,64-67. (Evidence Quality B)
Effects on daytime functions
Improvement in daytime sleepiness assessed by Epworth Sleepiness Scale is seen with usage of oral
appliances64,66,68. The assessment of neuropsychological function showed significant improvement in
measures of self-reported sleepiness, fatigue and energy levels and simulated driving performance68,69.
(Evidence Quality B)
Effects on vascular diseases
There is a modest favourable effect of OAs on systolic and diastolic blood pressure and on mean
arterial pressure70. (Evidence Quality A)
is better with mandibular advancement devices (MAD)
than any other appliance74,77,78.
(Evidence Quality C)
4.4.8 Other recent advances in the treatment of
OSA - Nasal EPAP device is a single-use device applied
over the nostrils that functions like an inspiratory valve
allowing unimpeded inspiration but offers resistance
to expiration, creating an EPAP. This resultant EPAP
cannot be titrated. In a large randomized controlled
trial (RCT), the nasal EPAP device significantly
improved AHI (43 vs. 10%) and ESS at three months
as compared to a sham device. However, some patients
do not show any improvement in AHI with nasal EPAP,
and among the responders not all would achieve an
AHI < 10 events/h. The clear-cut indication for nasal
EPAP devices is still not well defined79.
5 Surgical treatment of OSA
PAP therapy has been considered to be the first-line
of management for patients with OSAS80. However,
some patients may prefer alternative treatment options
because they are unable to tolerate, and are noncompliant81 or do not benefit from PAP therapy. The lack
of randomized controlled trials comparing PAP therapy
and surgical treatment make it very difficult to attain
a consensus in selecting the appropriate management
Box 6. Contraindications
therapy62,71,72
•
•
•
•
•
to
oral
appliance
(OA)
Inadequate number of healthy teeth in upper and lower
dental arch (At least 6-10 teeth in each arch desirable).
Periodontal diseases.
Patients with full dentures.
Limitation in forward protrusion of mandible and jaw
opening.
Temporo-mandibular joint diseases.
Box 7. Predictors of response to oral appliances73,74
Better response is seen with:(Evidence Quality C)
•• Female sex
•• Younger age
•• Lower BMI
•• Smaller neck circumference
•• Cephalometric parameters:
Short palate
Large retro-palatal airway space
Narrow anterior posterior position of mandible
(small SNB angle)
Higher anterior posterior position of the maxilla
(large SNA angle)
BMI, body mass index; SNA, sella nasion A; SNB, sella
nasion B
Box 8. Adverse Effects of oral appliances (OAs)75-77
Adverse effects of OAs (Evidence Quality C)
•
Excessive salivation
•
Temporary discomfort after awakening
•
Mucosal dryness
•
Transient discomfort in teeth, gum and Temporomandibular joint
•
Headache
•
Mesial migration of lower dentition
•
Distal migration of upper dentition
option82. The decision for surgical management should
be strictly individualized after careful assessment
of patient with due importance given to the sites of
obstruction. The following description provides an
insight into the procedures that are currently available
and their potential role in routine management.
5.1 Evaluation of level of obstruction: The most
significant concern in the assessment of airway is
that it can only be performed in an awake patient and
the scenario hardly simulates the exact status during
sleep. Apart from drug-induced sleep nasoendoscopy
[Downloaded free from http://www.ijmr.org.in on Saturday, November 01, 2014, IP: 117.203.194.44] || Click here to download free Android application for this journa
464
INDIAN J MED RES, September 2014
(DISE)83-85 in patients who are planned for surgery and
fiberopticnasopharyngoscopy with Mueller manoeuvre
(FNMM)86, other methods like cephalometry, acoustic
analysis, somnofluoroscopy, CT and sleep MRI are
not recommended for routine use to assess the level of
obstruction.
5.2 Surgeries in OSA: Surgical options in OSA are site
directed surgeries and bariatric surgery.
5.2.1 Nasal and nasopharyngeal surgery - Patients
with OSAS frequently have nasal obstruction which
results in snoring and mild sleep apnoea, but nasal
blockage per se does not lead to severe OSA.
1. Nasal surgery (correction of anatomical defects)
alone is not a useful method of treatment of moderate
to severe sleep apnoea87. (Evidence Quality B, Not
recommended).
2. It also improves the compliance with PAP and
also improves its effectiveness87,88. (Evidence Quality
B, Recommended).
5.2.2 Maxillo-mandibular surgeries - Malpositioning
of maxilla and mandible contribute to OSAS by reducing
the posterior hypopharyngeal space. Role of surgery
in the correction of such anatomical abnormalities is
summarized in Table VI89-98.
5.2.3 Role of bariatric surgery for treatment of
OSAS - Bariatric surgery (BS) is a surgery done in
order to create caloric restriction and/or malabsorption
for weight loss. The commonly performed bariatric
Table VI. Maxillo-mandibular surgeries
Genioglossus advancement
(Evidence Quality C, Optional
Recommendation)89
Genioglossus advancement is found to be helpful in patients with hypopharyngeal
soft tissue and tongue base abnormalities.The short- and long-term effects of
genioglossus advancement are improvement of Epworth scale, AHI score and
oxygen saturation.
Maxillo-mandibular
advancement surgery90
(Evidence Quality C, Optional
Recommendation)
Maxillo-mandibular advancement surgery is an option for severe OSA patients
with maxillary and mandibular retrusion, unable to tolerate PAP therapy and in
whom oral appliances have failed. It can also be considered in patients who have
failed to improve after other surgical procedures.
Distraction osteogenesis
(Evidence Quality C, Optional
Recommendation)91
Distraction osteogenesis can be employed in patients with severe OSA due to
maxillofacial skeletal disharmony, particularly mandibular and maxillary retrusion
where more than 10-12mm advancement is required.
Uvulopalatopharyngoplasty (UPPP)
(Evidence Quality C, Recommended in
patients with retropalatal obstruction)92,93
UPPP is the standard mode of management in patients with retropalatal
obstruction.
Laryngeal surgery
(Evidence Quality C, Recommended only for
patients with laryngeal pathology)94
Laryngeal surgery is limited to patients with laryngeal obstruction requiring surgical
excision for its management. PAP therapy is the primary mode of management in
patients with laryngeal pathology. Surgery is usually preferred for intractable cases
or patients with poor compliance to PAP.
Tonsillectomy
(Evidence Quality C, Recommended in
adults with tonsillar hypertrophy)95
Tonsillectomy is indicated in adults with tonsillar hypertrophy which is nonresponsive to medical management.
Multilevel surgery (MLS) in OSAS96,97
(Evidence Quality C, Recommended for cases
with documented multiple level obstruction)
Multilevel surgery refers to surgical procedures performed at two or more sites in the
upper airway. The three main levels of obstruction identified are nasal, retropalatal
and retroglossal/hypopharyngeal. MLS is a viable option for patients who failed
PAP or other conservative methods. The suitable candidates include those with
mild-moderate OSA, BMI <30kg/m2, age <60 years, retroglossal obstruction and
without any co-morbidity.
Tracheostomy for OSAS98
(Evidence Quality C, Optional
Recommendation)
Tracheostomy is poorly accepted in the present scenario. Patients with significant
OSA who have failed all medical and surgical procedures might require permanent
tracheostomy. It significantly decreases apnoea index, desaturation index, sleepiness
and mortality in OSA subjects but does not correct central apnoea.
[Downloaded free from http://www.ijmr.org.in on Saturday, November 01, 2014, IP: 117.203.194.44] || Click here to download free Android application for this journa
sharma et al: INOSA Guidelines 2014
procedures are adjustable gastric banding (AGB),
Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy
(SG) and bilio-pancreatic diversion (BPD).
5.2.3.1 Impact of BS on OSA: Following BS, there is
improvement of post-operative sleep quality, reduction
in day time sleepiness, improvement in quality of life,
decrease in use of PAP and decrease in use of high PAP
pressure requirement. Gastric bypass was the most
successful procedure in improving or resolving OSA
followed by gastroplasty, BPD and gastric banding
being the least effective procedure99. However, in the
majority of the patients (62%), the mean residual AHI
after surgery was more than 15 events per hour. This
indicates that there is a persistent residual disease,
even though there has been considerable improvement.
As such, all patients should undergo repeat PSG after
surgical weight loss and those patients who have residual
disease consistent with moderately severe OSA need
continued treatment with PAP. The available evidence
suggests that that the patients cured of OSA were less
obese and younger than those who had residual OSA
after bariatric surgery100.
In a recent meta-analysis of 13,900 patients who
underwent bariatric surgery, 79 per cent of patients
experienced either resolution or improvement of
their sleep apnoea. Bariatric surgery is strongly
recommended101 for obese OSA patients with BMI
≥35kg/m2 (Evidence Quality B).
Conflicts of interest: None
References
1.
2.
American Academy of Paediatrics Steering Committee
on Quality Improvement and Management. Classifying
Recommendations for Clinical Practice Guidelines. Pediatrics
2004; 114 : 874-7.
ICSD-3 Online Version - American Academy of Sleep
Medicine (AASM) AASM. Available from: http://www.
aasmnet.org/store/product.aspx?pid=849,
accessed
on
September 27, 2014.
465
6.
Lam JCM, Sharma SK, Lam B. Obstructive sleep apnoea:
definitions, epidemiology & natural history. Indian J Med Res
2010; 131 : 165-70.
7.
Al Lawati NM, Patel SR, Ayas NT. Epidemiology, risk factors,
and consequences of obstructive sleep apnea and short sleep
duration. Prog Cardiovasc Dis 2009; 51 : 285-93.
8.
Eckert DJ, Malhotra A. Pathophysiology of adult obstructive
sleep apnea. Proc Am Thorac Soc 2008; 5 : 144-53.
9.
Young T, Finn L, Peppard PE, Szklo-Coxe M, Austin D, Nieto
FJ, et al. Sleep disordered breathing and mortality: eighteenyear follow-up of the Wisconsin sleep cohort. Sleep 2008;
31 : 1071-8.
10. Montesi SB, Edwards BA, Malhotra A, Bakker JP. The effect
of continuous positive airway pressure treatment on blood
pressure: a systematic review and meta-analysis of randomized
controlled trials. J Clin Sleep Med 2012; 8 : 587-96.
11. Peppard PE, Young T, Palta M, Skatrud J. Prospective study
of the association between sleep-disordered breathing and
hypertension. N Engl J Med 2000; 342 : 1378-84.
12. Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R,
Niroumand M, et al. High prevalence of unrecognized sleep
apnoea in drug-resistant hypertension. J Hypertens 2001;
19 : 2271-7.
13. Hung J, Whitford EG, Parsons RW, Hillman DR. Association
of sleep apnoea with myocardial infarction in men. Lancet
1990; 336 : 261-4.
14. Herrscher TE, Akre H, Øverland B, Sandvik L, Westheim AS.
High prevalence of sleep apnea in heart failure outpatients:
even in patients with preserved systolic function. J Card Fail
2011; 17 : 420-5.
15. Gami AS, Pressman G, Caples SM, Kanagala R, Gard JJ,
Davison DE, et al. Association of atrial fibrillation and
obstructive sleep apnea. Circulation 2004; 110 : 364-7.
16. Johnson KG, Johnson DC. Frequency of sleep apnea in stroke
and TIA patients: a meta-analysis. J Clin Sleep Med 2010;
6 : 131-7.
17. Wang X, Bi Y, Zhang Q, Pan F. Obstructive sleep apnoea and
the risk of type 2 diabetes: a meta-analysis of prospective
cohort studies. Respirol Carlton Vic 2013; 18 : 140-6.
18. Robinson GV, Pepperell JCT, Segal HC, Davies RJO, Stradling
JR. Circulating cardiovascular risk factors in obstructive sleep
apnoea: data from randomised controlled trials. Thorax 2004;
59 : 777-82.
19. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PMA,
Wilding JPH. Obstructive sleep apnoea is independently
associated with an increased prevalence of metabolic
syndrome. Eur Heart J 2004; 25 : 735-41.
3.
Yaggi HK, Strohl KP. Adult obstructive sleep apnea/hypopnea
syndrome: definitions, risk factors, and pathogenesis. Clin
Chest Med 2010; 31 : 179-86.
4.
Sharma SK, Reddy EV, Sharma A, Kadhiravan T, Mishra HK,
Sreenivas V, et al. Prevalence and risk factors of syndrome Z
in urban Indians. Sleep Med 2010; 11 : 562-8.
20. Sharma H, Sharma SK, Kadhiravan T, Mehta M, Sreenivas
V, Gulati V, et al. Pattern & correlates of neurocognitive
dysfunction in Asian Indian adults with severe obstructive
sleep apnoea. Indian J Med Res 2010; 132 : 409-14.
5.
Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur
VK, et al. Rules for scoring respiratory events in sleep:
update of the 2007 AASM Manual for the Scoring of Sleep
and Associated Events. Deliberations of the Sleep Apnea
Definitions Task Force of the American Academy of Sleep
Medicine. J Clin Sleep Med 2012; 8 : 597-619.
22. Tregear S, Reston J, Schoelles K, Phillips B. Obstructive sleep
apnea and risk of motor vehicle crash: systematic review and
meta-analysis. J Clin Sleep Med 2009; 5 : 573-81.
21. Bucks RS, Olaithe M, Eastwood P. Neurocognitive function
in obstructive sleep apnoea: a meta-review. Respirol Carlton
Vic 2013; 18 : 61-70.
[Downloaded free from http://www.ijmr.org.in on Saturday, November 01, 2014, IP: 117.203.194.44] || Click here to download free Android application for this journa
466
INDIAN J MED RES, September 2014
23. Ejaz SM, Khawaja IS, Bhatia S, Hurwitz TD. Obstructive
sleep apnea and depression: a review. Innov Clin Neurosci
2011; 8 : 17-25.
24. Xu J, Huang P, Song B, Chen J-M. Effect of continuous
positive airway pressure on erectile dysfunction in patients
with obstructive sleep apnea syndrome: a meta-analysis.
Zhonghua Nan Ke Xue Natl J Androl 2013; 19 : 77-81.
25. Baldwin CM, Ervin A-M, Mays MZ, Robbins J, Shafazand
S, Walsleben J, et al. Sleep disturbances, quality of life, and
ethnicity: the Sleep Heart Health Study. J Clin Sleep Med
2010; 6 : 176-83.
26. Kapur VK. Obstructive sleep apnea: diagnosis, epidemiology,
and economics. Respir Care 2010; 55 : 1155-67.
27. Epstein LJ, Kristo D, Strollo PJ, Friedman N, Malhotra A, Patil
SP, et al. Clinical guidelines for the evaluation, management
and long-term care of obstructive sleep apnea in adults. J Clin
Sleep Med 2009; 5 : 263-76.
28. National Guidelines Clearinghouse (NGC). Management
of obstructive sleep apnoea/hypopnoea syndrome in adults.
A national clinical guideline. Available from: http://www.
guideline.gov/content.aspx?id=3878, accessed on September
22, 2014.
29. Johns MW. A new method for measuring daytime sleepiness:
the Epworth sleepiness scale. Sleep 1991; 14 : 540-5.
30. Balk EM, Moorthy D, Obadan NO, Patel K, Ip S, Chung M,
et al. Diagnosis and Treatment of Obstructive Sleep Apnea in
Adults. Rockville (MD): Agency for Healthcare Research and
Quality (US); 2011. Available from: http://www.ncbi.nlm.nih.
gov/books/NBK63560/, accessed on September 27, 2014.
31. Sharma SK, Vasudev C, Sinha S, Banga A, Pandey RM,
Handa KK. Validation of the modified Berlin questionnaire
to identify patients at risk for the obstructive sleep apnoea
syndrome. Indian J Med Res 2006; 124 : 281-90.
32. Collop NA, Anderson WM, Boehlecke B, Claman D,
Goldberg R, Gottlieb DJ, et al. Clinical guidelines for the use
of unattended portable monitors in the diagnosis of obstructive
sleep apnea in adult patients. Portable Monitoring Task Force
of the American Academy of Sleep Medicine. J Clin Sleep
Med 2007; 3 : 737-47.
33. Kushida CA, Littner MR, Hirshkowitz M, Morgenthaler TI,
Alessi CA, Bailey D, et al. Practice parameters for the use
of continuous and bilevel positive airway pressure devices
to treat adult patients with sleep-related breathing disorders.
Sleep 2006; 29 : 375-80.
34. Vaughn BV, Giallanza P. Technical review of polysomnography.
Chest 2008; 134 : 1310-9.
35. Iber C, Redline S, Kaplan Gilpin AM, Quan SF, Zhang
L, Gottlieb DJ, et al. Polysomnography performed in the
unattended home versus the attended laboratory setting--Sleep
Heart Health Study methodology. Sleep 2004; 27 : 536-40.
36. Collop NA, Tracy SL, Kapur V, Mehra R, Kuhlmann D,
Fleishman SA, et al. Obstructive sleep apnea devices for outof-center (OOC) testing: technology evaluation. J Clin Sleep
Med 2011; 7 : 531-48.
37. Kaw R, Chung F, Pasupuleti V, Mehta J, Gay PC, Hernandez
AV. Meta-analysis of the association between obstructive
sleep apnoea and postoperative outcome. Br J Anaesth 2012;
109 : 897-906.
38. Giles TL, Lasserson TJ, Smith BJ, White J, Wright J, Cates
CJ. Continuous positive airways pressure for obstructive
sleep apnoea in adults. Cochrane Database Syst Rev 2006;
1 : CD001106.
39. Clinical Guidelines for the Manual Titration of Positive
Airway Pressure in Patients with Obstructive Sleep Apnea. J
Clin Sleep Med 2008; 4 : 157-71.
40. Lloberes P, Ballester E, Montserrat JM, Botifoll E, Ramirez A,
Reolid A, et al. Comparison of manual and automatic CPAP
titration in patients with sleep apnea/hypopnea syndrome. Am
J Respir Crit Care Med 1996; 154 : 1755-8.
41. Reeves-Hoché MK, Hudgel DW, Meck R, Witteman R, Ross
A, Zwillich CW. Continuous versus bilevel positive airway
pressure for obstructive sleep apnea. Am J Respir Crit Care
Med 1995; 151 : 443-9.
42. Gay P, Weaver T, Loube D, Iber C, Positive Airway Pressure
Task Force, Standards of Practice Committee, et al. Evaluation
of positive airway pressure treatment for sleep related breathing
disorders in adults. Sleep 2006; 29 : 381-401.
43. Lin Y-N, Li Q-Y, Zhang X-J. Interaction between smoking
and obstructive sleep apnea: not just participants. Chin
Med J 2012; 125 : 3150-6.
44. Morgenthaler TI, Kapen S, Lee-Chiong T, Alessi C, Boehlecke
B, Brown T, et al. Practice parameters for the medical therapy
of obstructive sleep apnea. Sleep 2006; 29 : 1031-5.
45. Dobrosielski DA, Patil S, Schwartz AR, Bandeen-Roche K,
Stewart KJ. Effects of exercise and weight loss in older adults
with obstructive sleep apnea. Med Sci Sports Exerc 2014; May
27 [Epub ahead of print].
46. Johansson K, Neovius M, Lagerros YT, Harlid R, Rössner
S, Granath F, et al. Effect of a very low energy diet on
moderate and severe obstructive sleep apnoea in obese men: a
randomised controlled trial. BMJ 2009; 339 : b4609.
47. Ravesloot MJL, van Maanen JP, Dun L, de Vries N. The
undervalued potential of positional therapy in positiondependent snoring and obstructive sleep apnea-a review of the
literature. Sleep Breath 2013; 17 : 39-49.
48. Inoue Y, Takasaki Y, Yamashiro Y. Efficacy and safety of
adjunctive modafinil treatment on residual excessive daytime
sleepiness among nasal continuous positive airway pressuretreated japanese patients with obstructive sleep apnea
syndrome: a double-blind placebo-controlled study. J Clin
Sleep Med 2013; 9 : 751-7.
49. Kay GG, Feldman N. Effects of armodafinil on simulated
driving and self-report measures in obstructive sleep apnea
patients prior to treatment with continuous positive airway
pressure. J Clin Sleep Med 2013; 9 : 445-54.
50. Sullivan CE, Issa FG, Berthon-Jones M, Eves L. Reversal
of obstructive sleep apnoea by continuous positive airway
pressure applied through the nares. Lancet 1981; 1 : 862-5.
51. McNicholas WT. Cardiovascular outcomes of CPAP therapy
in obstructive sleep apnea syndrome. Am J Physiol Regul
Integr Comp Physiol 2007; 293 : R1666-70.
52. Denker MG, Cohen DL. Use of continuous positive airway
pressure for sleep apnea in the treatment of hypertension. Curr
Opin Nephrol Hypertens 2014; 23 : 462-7.
[Downloaded free from http://www.ijmr.org.in on Saturday, November 01, 2014, IP: 117.203.194.44] || Click here to download free Android application for this journa
sharma et al: INOSA Guidelines 2014
53. Shamsuzzaman ASM, Gersh BJ, Somers VK. Obstructive
sleep apnea: implications for cardiac and vascular disease.
JAMA 2003; 290 : 1906-14.
54. Marshall NS, Barnes M, Travier N, Campbell AJ, Pierce
RJ, McEvoy RD, et al. Continuous positive airway pressure
reduces daytime sleepiness in mild to moderate obstructive
sleep apnoea: a meta-analysis. Thorax 2006; 61 : 430-4.
55. Tkacova R, Rankin F, Fitzgerald FS, Floras JS, Bradley TD.
Effects of continuous positive airway pressure on obstructive
sleep apnea and left ventricular afterload in patients with heart
failure. Circulation 1998; 98 : 2269-75.
56. Weaver TE, Mancini C, Maislin G, Cater J, Staley B, Landis
JR, et al. Continuous positive airway pressure treatment of
sleepy patients with milder obstructive sleep apnea: results of
the CPAP Apnea Trial North American Program (CATNAP)
randomized clinical trial. Am J Respir Crit Care Med 2012;
186 : 677-83.
57. Meurice JC, Cornette A, Philip-Joet F, Pepin JL, Escourrou
P, Ingrand P, et al. Evaluation of autoCPAP devices in home
treatment of sleep apnea/hypopnea syndrome. Sleep Med
2007; 8 : 695-703.
58. Smith I, Lasserson TJ. Pressure modification for improving
usage of continuous positive airway pressure machines in
adults with obstructive sleep apnoea. Cochrane Database Syst
Rev 2009; 4 :CD003531.
59. Yetkin O, Kunter E, Gunen H. CPAP compliance in patients
with obstructive sleep apnea syndrome. Sleep Breath 2008;
12 : 365-7.
60. Bakker JP, Marshall NS. Flexible pressure delivery modification
of continuous positive airway pressure for obstructive sleep
apnea does not improve compliance with therapy: systematic
review and meta-analysis. Chest 2011; 139 : 1322-30.
61. Kushida CA, Morgenthaler TI, Littner MR, Alessi CA, Bailey
D, Coleman J, et al. Practice parameters for the treatment of
snoring and obstructive sleep apnea with oral appliances: an
update for 2005. Sleep 2006; 29 : 240-3.
62. Ahrens A, McGrath C, Hägg U. A systematic review of
the efficacy of oral appliance design in the management of
obstructive sleep apnoea. Eur J Orthod 2011; 33 : 318-24.
63. Ferguson KA, Cartwright R, Rogers R, Schmidt-Nowara W.
Oral appliances for snoring and obstructive sleep apnea: a
review. Sleep 2006; 29 : 244-62.
64. Li W, Xiao L, Hu J. The comparison of CPAP and oral
appliances in treatment of patients with OSA: a systematic
review and meta-analysis. Respir Care 2013; 58 : 1184-95.
65. Phillips CL, Grunstein RR, Darendeliler MA, Mihailidou AS,
Srinivasan VK, Yee BJ, et al. Health outcomes of continuous
positive airway pressure versus oral appliance treatment for
obstructive sleep apnea: a randomized controlled trial. Am J
Respir Crit Care Med 2013; 187 : 879-87.
467
68. Gagnadoux F, Fleury B, Vielle B, Pételle B, Meslier N,
N’Guyen XL, et al. Titrated mandibular advancement versus
positive airway pressure for sleep apnoea. Eur Respir J 2009;
34 : 914-20.
69. Hoekema A, Stegenga B, Bakker M, Brouwer WH, de Bont
LGM, Wijkstra PJ, et al. Simulated driving in obstructive sleep
apnoea-hypopnoea; effects of oral appliances and continuous
positive airway pressure. Sleep Breath Schlaf Atm 2007; 11 :
129-38.
70. Iftikhar IH, Hays ER, Iverson M-A, Magalang UJ, Maas AK.
Effect of oral appliances on blood pressure in obstructive
sleep apnea: a systematic review and meta-analysis. J Clin
Sleep Med 2013; 9 : 165-74.
71. Almeida FR, Lowe AA. Principles of oral appliance therapy
for the management of snoring and sleep disordered breathing.
Oral Maxillofac Surg Clin N Am 2009; 21 : 413-20.
72. Petit F-X, Pépin J-L, Bettega G, Sadek H, Raphaël B, Lévy P.
Mandibular advancement devices: rate of contraindications in
100 consecutive obstructive sleep apnea patients. Am J Respir
Crit Care Med 2002; 166 : 274-8.
73. Ng ATM, Darendeliler MA, Petocz P, Cistulli PA. Cephalometry
and prediction of oral appliance treatment outcome. Sleep
Breath Schlaf Atm 2012; 16 : 47-58.
74. Marklund M, Stenlund H, Franklin KA. Mandibular
advancement devices in 630 men and women with obstructive
sleep apnea and snoring: tolerability and predictors of
treatment success. Chest 2004; 125 : 1270-8.
75. Ueda H, Almeida FR, Lowe AA, Ruse ND. Changes in
occlusal contact area during oral appliance therapy assessed
on study models. Angle Orthod 2008; 78 : 866-72.
76. Hammond RJ, Gotsopoulos H, Shen G, Petocz P, Cistulli PA,
Darendeliler MA. A follow-up study of dental and skeletal
changes associated with mandibular advancement splint use
in obstructive sleep apnea. Am J Orthod Dentofac Orthop
2007; 132 : 806-14.
77. De Almeida FR, Lowe AA, Tsuiki S, Otsuka R, Wong M,
Fastlicht S, et al. Long-term compliance and side effects of oral
appliances used for the treatment of snoring and obstructive
sleep apnea syndrome. J Clin Sleep Med 2005; 1 : 143-52.
78. Jauhar S, Lyons MF, Banham SW, Cameron DA, Orchardson
R. Ten-year follow-up of mandibular advancement devices for
the management of snoring and sleep apnea. J Prosthet Dent
2008; 99 : 314-21.
79. Berry RB, Kryger MH, Massie CA. A novel nasal expiratory
positive airway pressure (EPAP) device for the treatment of
obstructive sleep apnea: a randomized controlled trial. Sleep
2011; 34 : 479-85.
66. Barnes M, McEvoy RD, Banks S, Tarquinio N, Murray CG,
Vowles N, et al. Efficacy of positive airway pressure and oral
appliance in mild to moderate obstructive sleep apnea. Am J
Respir Crit Care Med 2004; 170 : 656-64.
80. Haentjens P, Van Meerhaeghe A, Moscariello A, De Weerdt S,
Poppe K, Dupont A, et al. The impact of continuous positive
airway pressure on blood pressure in patients with obstructive
sleep apnea syndrome: evidence from a meta-analysis of
placebo-controlled randomized trials. Arch Intern Med 2007;
167 : 757-64.
67. Aarab G, Lobbezoo F, Hamburger HL, Naeije M. Effects of an
oral appliance with different mandibular protrusion positions
at a constant vertical dimension on obstructive sleep apnea.
Clin Oral Investig 2010; 14 : 339-45.
81. Sin DD, Mayers I, Man GCW, Pawluk L. Long-term
compliance rates to continuous positive airway pressure in
obstructive sleep apnea: a population-based study. Chest
2002; 121 : 430-5.
[Downloaded free from http://www.ijmr.org.in on Saturday, November 01, 2014, IP: 117.203.194.44] || Click here to download free Android application for this journa
468
INDIAN J MED RES, September 2014
82. Bridgman SA, Dunn KM. Surgery for obstructive sleep
apnoea. Cochrane Database Syst Rev 2000; 2 : CD001004.
uvulopalatopharyngoplasty for snoring. J Laryngol Otol 2000;
114 : 675-81.
83. Kotecha BT, Hannan SA, Khalil HMB, Georgalas C, Bailey P.
Sleep nasendoscopy: a 10-year retrospective audit study. Eur
Arch Oto-Rhino-Laryngol 2007; 264 : 1361-7.
93. Boot H, van Wegen R, Poublon RM, Bogaard JM,
Schmitz PI, van der Meché FG. Long-term results of
uvulopalatopharyngoplasty for obstructive sleep apnea
syndrome. Laryngoscope 2000; 110 : 469-75.
84. Soares D, Folbe AJ, Yoo G, Badr MS, Rowley JA, Lin H-S.
Drug-induced sleep endoscopy vs awake Müller’s maneuver in
the diagnosis of severe upper airway obstruction. OtolaryngolHead Neck Surg 2013; 148 : 151-6.
85. George JR, Chung S, Nielsen I, Goldberg AN, Miller A,
Kezirian EJ. Comparison of drug-induced sleep endoscopy and
lateral cephalometry in obstructive sleep apnea. Laryngoscope
2012; 122 : 2600-5.
86. Sher AE, Thorpy MJ, Shprintzen RJ, Spielman AJ, Burack
B, McGregor PA. Predictive value of Müller maneuver
in selection of patients for uvulopalatopharyngoplasty.
Laryngoscope 1985; 95 : 1483-7.
87. Li H-Y, Wang P-C, Chen Y-P, Lee L-A, Fang T-J, Lin H-C.
Critical appraisal and meta-analysis of nasal surgery for
obstructive sleep apnea. Am J Rhinol Allergy 2011; 25 : 45-9.
88. Nakata S, Noda A, Yagi H, Yanagi E, Mimura T, Okada T, et
al. Nasal resistance for determinant factor of nasal surgery in
CPAP failure patients with obstructive sleep apnea syndrome.
Rhinology 2005; 43 : 296-9.
89. Foltán R, Hoffmannová J, Pretl M, Donev F, Vlk M.
Genioglossus advancement and hyoid myotomy in treating
obstructive sleep apnoea syndrome - A follow-up study.
J Cranio-Maxillo-fac Surg 2007; 35 : 246-51.
90. Holty J-EC, Guilleminault C. Maxillomandibular advancement
for the treatment of obstructive sleep apnea: a systematic
review and meta-analysis. Sleep Med Rev 2010; 14 : 287-97.
91. Li KK, Powell NB, Riley RW, Guilleminault C. Distraction
osteogenesis in adult obstructive sleep apnea surgery: a
preliminary report. J Oral Maxillofac Surg 2002; 60 : 6-10.
92. Hicklin LA, Tostevin P, Dasan S. Retrospective survey
of long-term results and patient satisfaction with
94. Golz A, Goldenberg D, Netzer A, Westerman ST, Joachims
HZ. Epiglottic carcinoma presenting as obstructive sleep
apnea. J Otolaryngol 2001; 30 : 58-9.
95. Verse T, Kroker BA, Pirsig W, Brosch S. Tonsillectomy as a
treatment of obstructive sleep apnea in adults with tonsillar
hypertrophy. Laryngoscope 2000; 110 : 1556-9.
96. Lin H-C, Friedman M, Chang H-W, Gurpinar B. The efficacy
of multilevel surgery of the upper airway in adults with
obstructive sleep apnea/hypopnea syndrome. Laryngoscope
2008; 118 : 902-8.
97. Richard W, Kox D, den Herder C, van Tinteren H, de Vries
N. One stage multilevel surgery (uvulopalatopharyngoplasty,
hyoid suspension, radiofrequent ablation of the tongue base
with/without genioglossus advancement), in obstructive sleep
apnea syndrome. Eur Arch Oto-Rhino-Laryngol 2007; 264 :
439-44.
98. Camacho M, Certal V, Brietzke SE, Holty J-EC, Guilleminault
C, Capasso R. Tracheostomy as treatment for adult obstructive
sleep apnea: a systematic review and meta-analysis.
Laryngoscope 2014; 124 : 803-11.
99. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W,
Fahrbach K, et al. Bariatric surgery: a systematic review and
meta-analysis. JAMA 2004; 292 : 1724-37.
100. Greenburg DL, Lettieri CJ, Eliasson AH. Effects of surgical
weight loss on measures of obstructive sleep apnea: a metaanalysis. Am J Med 2009; 122 : 535-42.
101. Sarkhosh K, Switzer NJ, El-Hadi M, Birch DW, Shi X, Karmali
S. The impact of bariatric surgery on obstructive sleep apnea:
a systematic review. Obes Surg 2013; 23 : 414-23.
Reprint requests: Dr Surendra K. Sharma; Professor & Head; Department of Medicine
All India Institute of Medical Sciences, Anasari Nagar,
New Delhi 110 029, India
e-mail: sksharma.aiims@gmail.com
View publication stats